4 January 2016 - Sunesis Pharmaceuticals, Inc. today announced that the EMA has validated the Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed refractory acute myeloid leukemia in patients aged 60 years and older.

For more details, go to: http://ir.sunesis.com/phoenix.zhtml?c=194116&p=irol-newsArticle&ID=2125727